---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-24-000006"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T10:24:50.421983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q4 revenues $3.43B (+1% YoY); Dupixent up 31%; full-year guidance issued

## Summary
- Q4 GAAP EPS $10.19, non-GAAP $11.86; FY GAAP EPS $34.77, non-GAAP $43.79.
- Dupixent global net sales Q4 $3.22B (+31% YoY), FY $11.59B (+33%). EYLEA franchise U.S. net sales down 2% in Q4.
- Pipeline: Dupixent COPD sBLA and linvoseltamab BLA submitted; EYLEA HD approved in EU/Japan.
- FY2024 guidance: GAAP R&D $4.82-5.07B, SG&A $2.89-3.09B, gross margin 86-88%.
- Share repurchases $2.215B in FY2023; $1.5B remain. CFO Robert Landry to retire.

## SEC filing metadata
- accession: 0001804220-24-000006
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/0001804220-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/regn-20240202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-24-000006
- JSON: https://secwatch.observer/filing/0001804220-24-000006.json
- Plain text: https://secwatch.observer/filing/0001804220-24-000006.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported the quarter and year ended December 31, 2023 results: revenue $3.43 billion (Q4 2023), $13.12 billion (Full year 2023), net income $1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP), EPS $10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP).
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $3.43 billion (Q4 2023), $13.12 billion (Full year 2023)
  - Net income: $1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP)
  - EPS: $10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP)
  - Result: reported results
  source text: On February 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/0001804220-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.